Equities Analysts Set Expectations for Atossa Genetics Inc.’s FY2016 Earnings (ATOS)
Atossa Genetics Inc. (NASDAQ:ATOS) – Research analysts at Seethru Equity increased their FY2016 earnings per share (EPS) estimates for Atossa Genetics in a report released on Monday. Seethru Equity analyst A. Tandon now forecasts that the brokerage will post earnings per share of ($2.96) for the year, up from their prior estimate of ($3.60).
Shares of Atossa Genetics (NASDAQ:ATOS) opened at 2.06 on Wednesday. The stock’s 50 day moving average is $2.57 and its 200-day moving average is $3.96. Atossa Genetics has a 12 month low of $1.78 and a 12 month high of $12.60. The company’s market cap is $5.43 million.
Atossa Genetics (NASDAQ:ATOS) last posted its earnings results on Friday, August 12th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02.
About Atossa Genetics
Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.
Receive News & Stock Ratings for Atossa Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc. and related stocks with our FREE daily email newsletter.